Navigation Links
Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders
Date:7/22/2008

SOUTH SAN FRANCISCO, Calif., July 22 /PRNewswire/ -- Hyperion Therapeutics, Inc. today announced that it has completed patient enrollment in its Phase 1/2 clinical trial to evaluate the safety, tolerability and ammonia scavenging effects of HPN-100 (formally called GT4P) versus BUPHENYL(R) (sodium phenylbutyrate) in patients with urea cycle disorders (UCD). The company plans to announce top-line results in the fourth quarter of this year.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070905/AQW076LOGO)

"Completing enrollment in this Phase 1/2 study is an important milestone in our development program," said Bruce Scharschmidt, Chief Medical Officer of Hyperion Therapeutics. "This represents the first trial of HPN-100 in patients with UCDs and the results will be important in assessing its potential to improve care for these patients."

About Urea Cycle Disorder

UCDs are inherited, inborn errors of metabolism present in an estimated 1 in 10,000 births in the US. Patients with UCDs lack or are deficient in one of the key enzymes that comprise the urea cycle, the body's primary vehicle for removing ammonia, a potent neurotoxin, from the bloodstream. UCDs often present in the neonatal period, but onset can occur at any age depending on the severity of the disorder. Left untreated, UCDs can cause dangerously heightened levels of ammonia in the bloodstream (hyperammonemia) resulting in brain damage, coma, and/or death.

About HPN-100

HPN-100 is a pro-drug of phenylbutryrate and a pre-pro-drug of phenylacetic acid (PAA), the active moiety of BUPHENYL(R), the only therapy currently FDA-approved as adjunctive therapy for the chronic management of patients with the most prevalent urea cycle disorders -- carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), and argininosuccinic acid synthetase (AS). HPN-100, which is dosed orally in
'/>"/>

SOURCE Hyperion Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Hyperion Therapeutics Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of GT4P in Patients With Urea Cycle Disorders
2. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
6. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
7. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
8. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Clinicient Inc , a leader ... results of an industry survey of how efficiently ... practice owners and administrative staff completed the brand-neutral ... technology and services that improve therapist efficiency. ... published a free 12-page guide to help physical ...
(Date:5/26/2015)... DUBLIN , May 26, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/nghdvl/north_american ) has announced the addition of ... Entry Market by Type (Integrated Computerized Physician ... by Component (Hardware, Software, Services) - Forecast ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
(Date:5/26/2015)... 26, 2015  EndoChoice today announced the launch of ... common stock, which will represent 25.6% of its outstanding ... Delaware corporation in connection with the offering. ... be between $15 and $17 per share. The underwriters ... to purchase up to an additional 937,500 shares of ...
Breaking Medicine Technology:Survey: Half of Physical Therapists Underbill For Their Services 2North American Computerized Physician Order Entry Market 2015-2019 2EndoChoice Announces Launch of Its Initial Public Offering 2
... Crisis of Prematurity , , , ... June 16 The widespread use of fertility drugs, not just high-tech laboratory ... premature birth in the United States , experts said today at the March of ... , Working with experts ...
... June 16 The Regence Foundation announced today it has ...  The award recognizes leaders in the field of palliative care . ... grant associated with the award to support continued advancements in palliative care. ... Palliative care is ...
Cached Medicine Technology:Fertility Drugs Contribute Heavily to Multiple Births 2Fertility Drugs Contribute Heavily to Multiple Births 3Regence Foundation Honors Palliative Care Leaders 2Regence Foundation Honors Palliative Care Leaders 3
(Date:5/27/2015)... May 27, 2015 National ... partner, award winning web development and interactive ... announce the launch of its newly redesigned, ... , National Healthcare Providers, is a physician ... in the areas of Radiology, Anesthesiology, Emergency ...
(Date:5/27/2015)... CARSON, California (PRWEB) May 27, 2015 ... in quality drinking water filtration products, has announced ... system is one of the first to pass ... Compounds/Incidental Contaminants. The certification is monumental, proving that ... presence of select pharmaceuticals, over-the-counter medications, and chemicals ...
(Date:5/27/2015)... 2015 Net Pistol proudly welcomes two ... clients: , The Mobility Van Store of Lakeland, Florida, ... in the mobility industry. They have a team of ... or pre-owned wheelchair-accessible van, truck or car. Additionally, they ... lift chairs, three and four-wheel scooters, and manual wheelchairs. ...
(Date:5/27/2015)... The Advanced Fertility Center of Chicago announces that their ... better serve the needs of couples in Chicagoland. The ... Northwest side of the city at 4920 North Central Ave., ... the Chicago office at (773) 794–1818. This is the ... The other 2 offices are in Gurnee and Crystal ...
(Date:5/26/2015)... San Francisco, CA (PRWEB) May 27, 2015 ... innovative and beautiful technology for women, today announces ... jewelry that monitors women’s stress, sleep, activity and ... of jewelry with innovative health tracking technolo- gy, ... to stress levels, to provide women with lifestyle ...
Breaking Medicine News(10 mins):Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 2Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 3Health News:Water, Inc.’s BG-12000 Body Glove Water Filter System Receives NSF/ANSI Standard 401 Certification for Pharmaceutical Emerging Contaminant Reduction 2Health News:Water, Inc.’s BG-12000 Body Glove Water Filter System Receives NSF/ANSI Standard 401 Certification for Pharmaceutical Emerging Contaminant Reduction 3Health News:Net Pistol Continues Success Serving Mobility Dealers 2Health News:The Advanced Fertility Center of Chicago Opens a New Fertility Office Location in Chicago 2Health News:Bellabeat debuts the LEAF - smart jewelry that monitors women’s health. 2Health News:Bellabeat debuts the LEAF - smart jewelry that monitors women’s health. 3
... AED industry-leading commitment to research and developmentGrand opening ... the American Academy of Dermatology (AAD)HAYWARD, Calif., March ... SLTM ) today announced the opening of the ... new product development, facilitate research on the innovative ...
... of Cosmetic Dermatology Finds Over-the-Counter (OTC) Albolene(R) Moisturizing Cleanser as ... Mild to Moderate EczemaEDISON, N.J., March 5 Mild to ... to control and heal this skin condition without a prescription ... in the March 2009 issue of the Journal of ...
... of metabolic syndrome in strained unions, study finds , , THURSDAY, ... an unhappy marriage may be greater for women than men, ... in "strained" unions, those marked by arguing and being angry, ... women in the contentious relationships were more likely to develop ...
... InfoLogix ensures a hospital,s communications system enables more efficient ... nightmare is having its communications system go down. But ... InfoLogix, Inc. (Nasdaq: IFLG ), ... out one of America,s largest and most reliable wireless ...
... Finance New Health Care Proposals At Today,s Summit?WHITE HOUSE TO ... released today by the Republican National Committee:(Logo: http://www.newscom.com/cgi-bin/prnh/20080519/RNCLOGO ) ... Summit : ... On Health Care Issues. "On Thursday, Mr. Obama ...
... EU and US Approvals for Intravenous Formulation of Temozolomide ... PresentationKENILWORTH, N.J., March 5 Schering-Plough Corporation (NYSE: ... and the US FDA both approved the intravenous (IV) ... approved oral form of the drug. Temozolomide is ...
Cached Medicine News:Health News:Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center 2Health News:Solta Medical, Inc. Announces State-of-the-Art Aesthetic Center 3Health News:Commonly Used Beauty Staple Clinically Proven to Help Treat Eczema 2Health News:Commonly Used Beauty Staple Clinically Proven to Help Treat Eczema 3Health News:Bad Marriages Harder on Women's Health 2Health News:Bad Marriages Harder on Women's Health 3Health News:InfoLogix Implements Wireless Multi-Site Medical Communications Solution for Sisters of Mercy Health System 2Health News:InfoLogix Implements Wireless Multi-Site Medical Communications Solution for Sisters of Mercy Health System 3Health News:InfoLogix Implements Wireless Multi-Site Medical Communications Solution for Sisters of Mercy Health System 4Health News:InfoLogix Implements Wireless Multi-Site Medical Communications Solution for Sisters of Mercy Health System 5Health News:RNC: Tax and Spend Fever 2Health News:RNC: Tax and Spend Fever 3Health News:RNC: Tax and Spend Fever 4Health News:RNC: Tax and Spend Fever 5Health News:RNC: Tax and Spend Fever 6Health News:RNC: Tax and Spend Fever 7Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 2Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 3Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 4Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 5Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 6Health News:European Commission and United States Food and Drug Administration (FDA) Both Approve New Options for Patients With Certain Primary Brain Tumors 7
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Angled Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Titanium. Straight shafts with 6.5 mm tying platform. Round knurled handle with dull finish. Overall length 4.4 inches....
Titanium. Curved shafts with 5.5 mm tying platform. Round knurled handle with dull finish. Overall length 4.3 inches....
Medicine Products: